Harnessing the immune system for the treatment of non-small-cell lung cancer.
about
Trial WatchImmunotherapy for lung cancerCurrent and future molecular profiling of cancer by next-generation sequencingDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerEffect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive MicroenvironmentProgress in immunotherapy for non-small cell lung cancerPD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung CancerMolecular pathways and therapeutic targets in lung cancerBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerMolecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.Recent advances in immunotherapy for non-small-cell lung cancer.Novel agents in development for advanced non-small cell lung cancer.Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.Immune checkpoint inhibitors in NSCLC.Nivolumab in NSCLC: latest evidence and clinical potentialGefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy.PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancerImmune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.Objective measurement and clinical significance of TILs in non-small cell lung cancer.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer.Differentiated regulation of immune-response related genes between LUAD and LUSC subtypes of lung cancers.PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.Targeting the immune system in the treatment of non-small-cell lung cancer.Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy.Actual status of therapeutic vaccination in non-small cell lung cancerTherapeutic vaccines for cancer: an overview of clinical trials.Update on systemic therapy of advanced non-small-cell lung cancer.The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.Clinical cancer research: the past, present and the future.The hypoxic tumor microenvironment: driving the tumorigenesis of non-small-cell lung cancer.Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach.Immunotherapy in lung cancer.Best practice in the treatment of advanced squamous cell lung cancer.
P2860
Q24618653-9D1A85CC-255B-4E88-B8C5-879FD847A3AFQ26751254-E049E3FF-9469-4F03-8FD5-46D210ED377DQ26796272-90329922-6368-49EB-96AB-33E356E1D099Q26798047-3C63376F-3C44-4E62-8C54-E492A857219DQ26864045-AC11F2C9-2648-4679-8D58-F1A9E49A6C3AQ26865725-8D59459D-0E7C-4217-B290-F157851CA656Q27853353-A161EDFB-E62C-4BA5-8495-15CBA7A39866Q28084766-477437CE-A8D3-4E18-9B14-6E61E123ACB1Q33688872-B12BDBF6-C2CD-4F98-A8BB-FA10AA75D695Q33862861-083E7620-C90E-4173-B8AD-C2DBCB2B2B0CQ33912075-DF945FB5-28E8-4D5E-9839-4470D85AFE68Q34290801-484C9A05-4675-4A74-B931-2F40AA36AD92Q34389263-81E10C96-D121-437E-8436-8CA5E63488F0Q34417878-B851CAC5-FF6D-4ACD-8A95-7D7B053A150DQ34437570-9FCF1CEE-5FC2-4D5A-BB2B-3FB81305EAC7Q34466452-DE84DC42-E5FF-4091-8747-20B054C38CC8Q34774866-A96B134B-59BC-4BF9-B693-88D7DB208A6EQ35713307-56CA71DE-6752-4361-8DEA-12143D48B45EQ35944106-7AA778B3-27F7-4993-B1D6-C64BE98E8072Q36047422-D2DDFE49-0FCF-4317-8615-A64620A8FDA9Q36999705-45917D75-7DD7-40B0-8662-97C906AA54EBQ37684483-CBD1B887-2C23-48F0-8B48-B576418EDACCQ37702094-7FAB97CA-2C9F-4548-9867-CD4A63489E6DQ37741383-49AB6044-E8DB-40D5-9A54-F9C0771864D2Q38128228-5B616D0F-52DA-4E55-BF3F-E776A4D319E7Q38143201-1AEC16A4-C3B7-41C4-8335-38D347817620Q38202161-2BB03A7A-E435-4C45-800A-102A551453EEQ38207907-FC6F28B9-5AAF-49A4-BEBA-8D633E8418DFQ38222469-93E3AE37-BE5B-4929-BBBA-CABC4326BF07Q38223388-2B5C4E70-67DF-4A0C-8DE4-20062983A9DDQ38227030-D6642499-6DA4-4AA0-ADC1-C1E5CDF787D3Q38237463-0CA48305-B187-4008-85A4-65BE0C0B94B1Q38248051-CDA4BFAF-E401-4AFC-B38B-9BDE775A09D1Q38250205-74171EF1-9CC7-4EEB-A8F3-9FB30000A2EBQ38253280-0B1EE586-040C-4333-A02E-655D5FE77393Q38296670-F47310FC-1618-4DAC-A3F4-29B752248F0EQ38349665-60E27445-84DF-4E35-BE07-F4C1916DBF95Q38352879-0677D16B-C36E-4ECD-8381-84AE11DA1781Q38390093-98F732BE-AA2A-4ABB-9B06-2838E9F053A7Q38435967-B30FF87E-37E6-4AB2-9985-8ABDCCDF9E5F
P2860
Harnessing the immune system for the treatment of non-small-cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Harnessing the immune system for the treatment of non-small-cell lung cancer.
@en
type
label
Harnessing the immune system for the treatment of non-small-cell lung cancer.
@en
prefLabel
Harnessing the immune system for the treatment of non-small-cell lung cancer.
@en
P356
P1476
Harnessing the immune system for the treatment of non-small-cell lung cancer.
@en
P2093
Julie R Brahmer
P304
P356
10.1200/JCO.2012.45.8703
P407
P577
2013-02-11T00:00:00Z